MDT vs SYK: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
MDT and SYK are similarly sized, but MDT trades noticeably cheaper on forward earnings (14.78x vs 17.66x): the market is paying up for SYK's profile and pricing MDT more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
MDT vs SYK: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | MDT | SYK | What it tells you |
|---|---|---|---|
| Market cap | $121.20B | $113.02B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 14.78 | 17.66 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 23.28 | 29.44 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.57 | 0.78 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 65% of range | 22% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.41 | 4.71 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: MDT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how MDT and SYK affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MDT and SYK share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MDT and SYK exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Medtronic (MDT) do?
Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Its business spans three main areas after October 2026: Cardiovascular (pacemakers, defibrillators, heart valves, and cardiac ablation), Neuroscience (spine implants, neuromodulation for pain and movement disorders, and surgical navigation), and Medical Surgical (surgical stapling, energy devices, and a growing robotic-surgery platform). Its former Diabetes unit (insulin pumps and continuous glucose monitoring) was carved out as MiniMed, which listed on Nasdaq under MMED; on October 15, 2026 Medtronic exchanged its remaining 252.8 million MiniMed shares for Medtronic shares in an exchange offer that was 5.4 times subscribed, so it no longer owns any of MiniMed. The company sells primarily to hospitals, surgeons, and health systems, generating durable, recurring demand tied to procedure volumes and chronic-disease management. Medtronic's scale gives it deep relationships with providers, a large installed base of devices, and the resources to fund extensive R&D and acquisitions. Growth depends on new product cycles, pipeline approvals, and global expansion, especially in emerging markets. Founded in 1949 and headquartered in Ireland for tax purposes (operationally rooted in Minnesota), Medtronic is a large-cap, dividend-growing medical-technology company tied to long-term healthcare demand and aging demographics, with trailing revenue of about $37.5 billion as of October 2026.
What does Stryker Corporation (SYK) do?
Stryker Corporation is a global medical technology company organized into two reportable segments: MedSurg and Neurotechnology (about 62% of 2025 sales) and Orthopaedics (about 38%). Its products include surgical instruments and navigation, endoscopy and communications systems, patient handling and emergency medical equipment, minimally invasive vascular and neurovascular devices, and orthopaedic implants for hips, knees, and trauma. The company's signature differentiator is Mako robotic-arm assisted surgery, which pulls hospitals into Stryker's ecosystem of implants and enabling technology; in early 2026 Stryker recast its Orthopaedics operations into a new Ortho Tech business that pairs orthopaedic instruments with Mako and enabling technologies.
MDT vs SYK: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- MDT drivers: Diversified device portfolio; Innovation pipeline and new product cycles.
- SYK drivers: Mako robotics and enabling technology; MedSurg and Neurotechnology breadth.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. For SYK, stryker still trades at a premium to many medtech peers, so any further slowdown in organic growth or margin progress can pressure the multiple, even after the stock fell about 20% over the past year.
MDT or SYK: which should you pick?
MDT vs SYK: the full fundamentals
MDT. At about $95 on October 16, 2026, Medtronic trades near 15 times forward earnings, a moderate multiple next to faster-growing medtech peers, while the GAAP trailing P/E of about 23x includes acquisition amortization. The 25 analysts tracked by Yahoo Finance hold a mean target near $104. The next report, expected around November 17, 2026, will be the first read on the company after the MiniMed exit, with consensus at about $1.33 of EPS on $9.5 billion of revenue.
SYK. Stryker closed near $294 on October 16, 2026, down about 16% this year, which has pulled its forward P/E to roughly 18x from about 22x in mid-2026. Q2 2026 beat estimates after a Q1 miss tied to the cyber incident, and trailing free cash flow is about $4.1 billion. Q3 results are due October 29, 2026, with consensus near $3.55 EPS on ~$6.6 billion of revenue.
Headline figures (approximate, October 2026): MDT shows revenue (ttm) ~$37.5 billion, up ~14% year over year in the July 2026 quarter, margins ~65% gross, ~19% operating, ~14% net, net income (ttm) ~$5.2 billion, eps ~$4.07 GAAP trailing; ~$6.41 forward estimate; SYK shows revenue (ttm) ~$25.8B (Q2 up ~9%), q2 2026 adj. eps $3.69 vs ~$3.49 est., net income (ttm) ~$3.7B, gross / operating margin ~66% / ~27%.
The bottom line: MDT vs SYK
MDT and SYK are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MDT and SYK exposure against your real portfolio. It is not an investment adviser.
Wondering how MDT or SYK fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Medtronic with AI
Connect the broker you already use and ask Walnut's AI how MDT fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between MDT and SYK?
+
Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Stryker Corporation is a global medical technology company organized into two reportable segments: MedSurg and Neurotechnology (about 62% of 2025 sales) and Orthopaedics (about 38%). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is MDT or SYK the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, MDT or SYK?
+
On forward P/E (as of October 2026), MDT trades at 14.78x and SYK at 17.66x, so MDT is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both MDT and SYK?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of MDT vs SYK?
+
MDT: Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. The Hugo robotic platform faces an entrenched Intuitive Surgical. The MiniMed separation removes diabetes but adds near-term noise: reported results, guidance and comparisons will shift as the unit leaves the numbers, and analysts expect EPS of about $1.33 for the quarter ending October 2026, slightly below the year-earlier level. Device companies face reimbursement pressure, hospital budget constraints, FDA approval and recall risk, and litigation exposure. A large international footprint brings currency headwinds, and debt stood near $28 billion against about $8.8 billion of cash as of October 2026. The stock is roughly flat over the past year despite faster sales growth. New-product execution, pipeline timing, and the ability to sustain organic growth remain the key swing factors for the investment case. SYK: Stryker still trades at a premium to many medtech peers, so any further slowdown in organic growth or margin progress can pressure the multiple, even after the stock fell about 20% over the past year. Q1 2026 results were hurt by a late-quarter cyber incident that missed EPS estimates, and in September management flagged peripheral vascular supply constraints likely lasting into Q4 plus slower summer hip sales. A CEO transition adds leadership uncertainty, and the $400 million CMR Surgical investment, with an option to acquire, brings execution risk in a soft-tissue robotics market dominated by Intuitive Surgical. The company faces strong competition in robotics and implants from Zimmer Biomet, Johnson & Johnson, Medtronic, and Smith and Nephew, plus pricing pressure from hospitals and payers. Integration risk from frequent acquisitions, currency swings, debt of about $15.5 billion, and regulatory or reimbursement changes add further uncertainty. Elective-procedure volumes can also be sensitive to macro and hospital-capacity conditions.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell MDT or SYK; figures are approximate and dated (as of October 2026). Verify current data before investing.